Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nano Drug Delivery Systems for Cancer Therapy
share announcement

Nano Drug Delivery Systems for Cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 14119

Special Issue Editors

Dr. Abhishek Sahu

E-Mail Website
Guest Editor
School of Materials Science and Engineering (SMSE), Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea
Interests: nanomedicine; cancer therapy; hypoxia; nanozyme; anti-inflammation
Dr. Thavasyappan Thambi

E-Mail Website
Guest Editor
Department of Bioengineering, Hanyang University, Seoul 04763, Korea
Interests: nanomedicine; stimuli-responsive polymers; injectable gels; chemoimmununotherapy; theranostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to a Special Issue of Pharmaceutics titled “Nano Drug Delivery Systems for Cancer Therapy”.

Despite the significant progress in medical science, cancer remains one of the deadliest diseases worldwide. In the last two decades, nanotechnology has made significant contributions to the fight against cancer. Particularly, nano-drug delivery systems have emerged as a promising method to improve the efficacy of traditional chemotherapeutics and reduce systemic toxicity. Owing to their outstanding features, nano-drug delivery systems are at the forefront of the development of new modes of cancer therapy (phototherapy, sonodynamic therapy, chemodynamic therapy, etc.). In addition, nano-drug delivery systems are also being used in cancer immunotherapy, cancer vaccine, and modulation of the tumor microenvironment to improve therapeutic effect.

This Special Issue focuses on the recent developments and new approaches towards nanoparticle-based drug delivery systems for cancer therapy. Emphasis will be on the design of smart, stimuli-sensitive drug delivery systems as well as nanosystems devoted to tumor microenvironment modulation and immunotherapy.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the design, synthesis, and characterization of nanoparticles for the delivery of anticancer drugs, siRNA, photosensitizers, etc. Applications of nano drug delivery systems for cancer immunotherapy, phototherapy, and chemo/sonodynamic therapy, and the development of pH- or ROS-sensitive nanosystems towards targeted drug release are especially welcome.

We look forward to receiving your contributions.

Dr. Abhishek Sahu
Dr. Thavasyappan Thambi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • cancer therapy
  • tumor targeting
  • drug delivery
  • gene delivery
  • photothermal therapy
  • photodynamic therapy
  • sonodynamic therapy
  • immunotherapy

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 4236 KiB  
Article
Therapeutic Application of Metal–Organic Frameworks Composed of Copper, Cobalt, and Zinc: Their Anticancer Activity and Mechanism
by Ihn Han, Seung Ah Choi and Do Nam Lee
Pharmaceutics 2022, 14(2), 378; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14020378 - 08 Feb 2022
Cited by 12 | Viewed by 2283
Abstract
Effective penetration into cells, or binding to cell membranes is an essential property of an effective nanoparticle drug delivery system (DDS). Nanoparticles are generally internalized through active transport mechanisms such as apoptosis, and cargo can be released directly into the cytoplasm. A metal–organic [...] Read more.
Effective penetration into cells, or binding to cell membranes is an essential property of an effective nanoparticle drug delivery system (DDS). Nanoparticles are generally internalized through active transport mechanisms such as apoptosis, and cargo can be released directly into the cytoplasm. A metal–organic framework (MOF) is a network structure consisting of metal clusters connected by organic linkers with high porosity; MOFs provide a desirable combination of structural features that can be adjusted with large cargo payloads, along with Cu, Co, and Zn-MOFs, which have the chemical stability required for water-soluble use. Bioactive MOFs containing copper, cobalt, and zinc were prepared by modifying previous methods as therapeutic drugs. Their structures were characterized via PXRD, single-crystal crystallographic analysis, and FT-IR. The degradability of MOFs was measured in media such as deionized water or DPBS by PXRD, SEM, and ICP-MS. Furthermore, we investigated the anticancer activity of MOFs against the cell lines SKOV3, U87MG, and LN229, as well as their biocompatibility with normal fibroblast cells. The results show that a nanoporous 3D Cu-MOF could potentially be a promising candidate for chemoprevention and chemotherapy. Full article
(This article belongs to the Special Issue Nano Drug Delivery Systems for Cancer Therapy)
►▼ Show Figures

Graphical abstract

11 pages, 2971 KiB  
Article
Biocompatible Core–Shell-Structured Si-Based NiO Nanoflowers and Their Anticancer Activity
by Kihak Gwon, Jong-Deok Park, Seonhwa Lee, Jong-Sung Yu and Do Nam Lee
Pharmaceutics 2022, 14(2), 268; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14020268 - 23 Jan 2022
Cited by 7 | Viewed by 2722
Abstract
Compared to most of nano-sized particles, core–shell-structured nanoflowers have received great attention as bioactive materials because of their high surface area with the flower-like structures. In this study, core–shell-structured Si-based NiO nanoflowers, Si@NiO, were prepared by a modified chemical bath deposition method followed [...] Read more.
Compared to most of nano-sized particles, core–shell-structured nanoflowers have received great attention as bioactive materials because of their high surface area with the flower-like structures. In this study, core–shell-structured Si-based NiO nanoflowers, Si@NiO, were prepared by a modified chemical bath deposition method followed by thermal reduction. The crystal morphology and basic structure of the composites were characterized by powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), specific surface area (BET) and porosity analysis (BJT), and inductively coupled plasma optical emission spectrometry (ICP-OES). The electrochemical properties of the Si@NiO nanoflowers were examined through the redox reaction of ascorbic acid with the metal ions present on the surface of the core–shell nanoflowers. This reaction favored the formation of reactive oxygen species. The Si@NiO nanoflowers showed excellent anticancer activity and low cytotoxicity toward the human breast cancer cell line (MCF-7) and mouse embryonic fibroblasts (MEFs), respectively, demonstrating that the anticancer activities of the Si@NiO nanoflowers were primarily derived from the oxidative capacity of the metal ions on the surface, rather than from the released metal ions. Thus, this proves that Si-based NiO nanoflowers can act as a promising candidate for therapeutic applications. Full article
(This article belongs to the Special Issue Nano Drug Delivery Systems for Cancer Therapy)
►▼ Show Figures

Graphical abstract

11 pages, 2823 KiB  
Article
Tumor-Targeted ZW800-1 Analog for Enhanced Tumor Imaging and Photothermal Therapy
by Min-Ho Park, Gayoung Jo, Eun-Jeong Kim and Hoon Hyun
Pharmaceutics 2021, 13(10), 1648; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13101648 - 09 Oct 2021
Cited by 7 | Viewed by 1761
Abstract
ZW800-1, a representative zwitterionic near-infrared (NIR) fluorophore, can minimize background tissue uptake owing to its balanced surface charges, and therefore, is widely used for improved NIR fluorescence imaging. As ZW800-1 has no tumor targetability, tumor imaging is highly dependent on the ability of [...] Read more.
ZW800-1, a representative zwitterionic near-infrared (NIR) fluorophore, can minimize background tissue uptake owing to its balanced surface charges, and therefore, is widely used for improved NIR fluorescence imaging. As ZW800-1 has no tumor targetability, tumor imaging is highly dependent on the ability of the molecules conjugated to the ZW800-1. To enable tumor targeting using ZW800-1 without additional conjugation, we developed a tumor-targetable and renal-clearable ZW800-1 analog (ZW800-AM) based on the structural modification of ZW800-1. Specifically, an amine group on the center linker of the ZW800-1 indocyanine backbone was modified by replacing phenoxypropionic acid with tyramine linkage on the meso-chlorine atom. This modification improved the tumor targeting ability, which is known as the structure-inherent targeting strategy. More importantly, ZW800-AM not only showed sufficient tumor accumulation without nonspecific uptake but also produced a photothermal effect, killing tumor cells under 808 nm NIR laser irradiation. In addition, ZW800-AM exhibited rapid renal elimination from the body within 4 h of injection, similar to ZW800-1. Overall, the discovery of ZW800-AM as a bifunctional phototherapeutic agent may provide an ideal alternative for tumor-targeted imaging and phototherapy. Full article
(This article belongs to the Special Issue Nano Drug Delivery Systems for Cancer Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 3938 KiB  
Review
Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review
by Yosif Almoshari
Pharmaceutics 2022, 14(3), 600; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14030600 - 09 Mar 2022
Cited by 26 | Viewed by 3490
Abstract
Cancer is a group of disorders characterized by aberrant gene function and alterations in gene expression patterns. In 2020, it was anticipated that 19 million new cancer cases would be diagnosed globally, with around 10 million cancer deaths. Late diagnosis and interventions are [...] Read more.
Cancer is a group of disorders characterized by aberrant gene function and alterations in gene expression patterns. In 2020, it was anticipated that 19 million new cancer cases would be diagnosed globally, with around 10 million cancer deaths. Late diagnosis and interventions are the leading causes of cancer-related mortality. In addition, the absence of comprehensive cancer therapy adds to the burden. Many lyotropic non-lamellar liquid-crystalline-nanoparticle-mediated formulations have been developed in the last few decades, with promising results in drug delivery, therapeutics, and diagnostics. Cubosomes are nano-structured liquid-crystalline particles made of specific amphiphilic lipids in particular proportions. Their ability to encapsulate lipophilic, hydrophilic, and amphiphilic molecules within their structure makes them one of a kind. They are biocompatible, versatile drug carriers that can deliver medications through various routes of administration. Many preclinical studies on the use of cubosomes in cancer treatment and theranostic applications have been conducted. However, before cubosomes may be employed in clinical practice, significant technical advances must be accomplished. This review summarizes the development of cubosomes and their multifunctional role in cancer treatment based on the most recent reports. Full article
(This article belongs to the Special Issue Nano Drug Delivery Systems for Cancer Therapy)
►▼ Show Figures

Figure 1

34 pages, 36094 KiB  
Review
Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges
by Md. Rizwanullah, Mohammad Zaki Ahmad, Mohammed M. Ghoneim, Sultan Alshehri, Syed Sarim Imam, Shadab Md, Nabil A. Alhakamy, Keerti Jain and Javed Ahmad
Pharmaceutics 2021, 13(12), 2039; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13122039 - 29 Nov 2021
Cited by 13 | Viewed by 3054
Abstract
Breast cancer therapeutic intervention continues to be ambiguous owing to the lack of strategies for targeted transport and receptor-mediated uptake of drugs by cancer cells. In addition to this, sporadic tumor microenvironment, prominent restrictions with conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer [...] Read more.
Breast cancer therapeutic intervention continues to be ambiguous owing to the lack of strategies for targeted transport and receptor-mediated uptake of drugs by cancer cells. In addition to this, sporadic tumor microenvironment, prominent restrictions with conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells possess a big challenge to even otherwise optimal and efficacious breast cancer treatment strategies. Surface-modified nanomedicines can expedite the cellular uptake and delivery of drug-loaded nanoparticulate constructs through binding with specific receptors overexpressed aberrantly on the tumor cell. The present review elucidates the interesting yet challenging concept of targeted delivery approaches by exploiting different types of nanoparticulate systems with multiple targeting ligands to target overexpressed receptors of breast cancer cells. The therapeutic efficacy of these novel approaches in preclinical models is also comprehensively discussed in this review. It is concluded from critical analysis of related literature that insight into the translational gap between laboratories and clinical settings would provide the possible future directions to plug the loopholes in the process of development of these receptor-targeted nanomedicines for the treatment of breast cancer. Full article
(This article belongs to the Special Issue Nano Drug Delivery Systems for Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop